Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Journal of environmental and public health ; 2022, 2022.
Article in English | EuropePMC | ID: covidwho-1999653

ABSTRACT

The sudden global pandemic of COVID-19 occurred in Malaysia at the beginning of new 2020, which increased the uncertainty of the economy. As a highly demanded industry during diseases, COVID-19-related news had a mixed influence on investors' confidence in the healthcare industry, so the short-term market reaction of the Malaysian healthcare industry is investigated during this unfolding event. This paper examines whether the “lockdown” suppressed the influence of COVID-19 pandemic on stock performance in 12 listed healthcare companies in Malaysia. We consider the “lockdown” order has different impacts on samples. The hardest hit among the four events is the first announcement of lockdown, whose cumulative average abnormal return (CAAR) is negative (CAAR<0), for its strict movement control. However, the impacts of the following three lockdown events are positive and less severe as the market gradually digest these kinds of news and the deregulation of movement control. Previous studies have justified the influence of disease outbreaks on the stock market;however, this study compensates for other studies by employing the event study methodology (ESM) approach to provide the first empirical evidence of the unprecedented influence of “lockdown” on Malaysian healthcare stock market. This study has practical implications for Malaysian financial markets that the lockdown orders matter for the Malaysian healthcare industry. The empirical results show that the stock market has positively affected the lockdown announcement after the first event. In turn, the policymakers could draw on these results related to stock performance to modify the regulations in the healthcare industry.

2.
Infect Dis Poverty ; 11(1): 74, 2022 Jun 29.
Article in English | MEDLINE | ID: covidwho-1910355

ABSTRACT

BACKGROUND: During the coronavirus disease 2019 (COVID-19) pandemic, seasonal influenza activity declined globally and remained below previous seasonal levels, but intensified in China since 2021. Preventive measures to COVID-19 accompanied by different epidemic characteristics of influenza in different regions of the world. To better respond to influenza outbreaks under the COVID-19 pandemic, we analyzed the epidemiology, antigenic and genetic characteristics, and antiviral susceptibility of influenza viruses in the mainland of China during 2020-2021. METHODS: Respiratory specimens from influenza like illness cases were collected by sentinel hospitals and sent to network laboratories in Chinese National Influenza Surveillance Network. Antigenic mutation analysis of influenza virus isolates was performed by hemagglutination inhibition assay. Next-generation sequencing was used for genetic analyses. We also conducted molecular characterization and phylogenetic analysis of circulating influenza viruses. Viruses were tested for resistance to antiviral medications using phenotypic and/or sequence-based methods. RESULTS: In the mainland of China, influenza activity recovered in 2021 compared with that in 2020 and intensified during the traditional influenza winter season, but it did not exceed the peak in previous years. Almost all viruses isolated during the study period were of the B/Victoria lineage and were characterized by genetic diversity, with the subgroup 1A.3a.2 viruses currently predominated. 37.8% viruses tested were antigenically similar to reference viruses representing the components of the vaccine for the 2020-2021 and 2021-2022 Northern Hemisphere influenza seasons. In addition, China has a unique subgroup of 1A.3a.1 viruses. All viruses tested were sensitive to neuraminidase inhibitors and endonuclease inhibitors, except two B/Victoria lineage viruses identified to have reduced sensitivity to neuraminidase inhibitors. CONCLUSIONS: Influenza activity increased in the mainland of China in 2021, and caused flu season in the winter of 2021-2022. Although the diversity of influenza (sub)type decreases, B/Victoria lineage viruses show increased genetic and antigenic diversity. The world needs to be fully prepared for the co-epidemic of influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus globally.


Subject(s)
COVID-19 , Influenza, Human , Orthomyxoviridae , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , COVID-19/epidemiology , China/epidemiology , Humans , Influenza, Human/epidemiology , Neuraminidase/genetics , Orthomyxoviridae/genetics , Pandemics , Phylogeny , SARS-CoV-2 , Seasons
3.
Infect Dis Poverty ; 11(1): 57, 2022 May 22.
Article in English | MEDLINE | ID: covidwho-1902417

ABSTRACT

BACKGROUND: A One Health approach has been increasingly mainstreamed by the international community, as it provides for holistic thinking in recognizing the close links and inter-dependence of the health of humans, animals and the environment. However, the dearth of real-world evidence has hampered application of a One Health approach in shaping policies and practice. This study proposes the development of a potential evaluation tool for One Health performance, in order to contribute to the scientific measurement of One Health approach and the identification of gaps where One Health capacity building is most urgently needed. METHODS: We describe five steps towards a global One Health index (GOHI), including (i) framework formulation; (ii) indicator selection; (iii) database building; (iv) weight determination; and (v) GOHI scores calculation. A cell-like framework for GOHI is proposed, which comprises an external drivers index (EDI), an intrinsic drivers index (IDI) and a core drivers index (CDI). We construct the indicator scheme for GOHI based on this framework after multiple rounds of panel discussions with our expert advisory committee. A fuzzy analytical hierarchy process is adopted to determine the weights for each of the indicators. RESULTS: The weighted indicator scheme of GOHI comprises three first-level indicators, 13 second-level indicators, and 57 third-level indicators. According to the pilot analysis based on the data from more than 200 countries/territories the GOHI scores overall are far from ideal (the highest score of 65.0 out of a maximum score of 100), and we found considerable variations among different countries/territories (31.8-65.0). The results from the pilot analysis are consistent with the results from a literature review, which suggests that a GOHI as a potential tool for the assessment of One Health performance might be feasible. CONCLUSIONS: GOHI-subject to rigorous validation-would represent the world's first evaluation tool that constructs the conceptual framework from a holistic perspective of One Health. Future application of GOHI might promote a common understanding of a strong One Health approach and provide reference for promoting effective measures to strengthen One Health capacity building. With further adaptations under various scenarios, GOHI, along with its technical protocols and databases, will be updated regularly to address current technical limitations, and capture new knowledge.


Subject(s)
One Health , Forecasting , Global Health
4.
Frontiers in pharmacology ; 13, 2022.
Article in English | EuropePMC | ID: covidwho-1897880

ABSTRACT

Objective: People suffering from coronavirus disease 2019 (COVID-19) are prone to develop pulmonary fibrosis (PF), but there is currently no definitive treatment for COVID-19/PF co-occurrence. Kaempferol with promising antiviral and anti-fibrotic effects is expected to become a potential treatment for COVID-19 and PF comorbidities. Therefore, this study explored the targets and molecular mechanisms of kaempferol against COVID-19/PF co-occurrence by bioinformatics and network pharmacology. Methods: Various open-source databases and Venn Diagram tool were applied to confirm the targets of kaempferol against COVID-19/PF co-occurrence. Protein-protein interaction (PPI), MCODE, key transcription factors, tissue-specific enrichment, molecular docking, Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were used to clarify the influential molecular mechanisms of kaempferol against COVID-19 and PF comorbidities. Results: 290 targets and 203 transcription factors of kaempferol against COVID-19/PF co-occurrence were captured. Epidermal growth factor receptor (EGFR), proto-oncogene tyrosine-protein kinase SRC (SRC), mitogen-activated protein kinase 3 (MAPK3), mitogen-activated protein kinase 1 (MAPK1), mitogen-activated protein kinase 8 (MAPK8), RAC-alpha serine/threonine-protein kinase (AKT1), transcription factor p65 (RELA) and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) were identified as the most critical targets, and kaempferol showed effective binding activities with the above critical eight targets. Further, anti-COVID-19/PF co-occurrence effects of kaempferol were associated with the regulation of inflammation, oxidative stress, immunity, virus infection, cell growth process and metabolism. EGFR, interleukin 17 (IL-17), tumor necrosis factor (TNF), hypoxia inducible factor 1 (HIF-1), phosphoinositide 3-kinase/AKT serine/threonine kinase (PI3K/AKT) and Toll-like receptor signaling pathways were identified as the key anti-COVID-19/PF co-occurrence pathways. Conclusion: Kaempferol is a candidate treatment for COVID-19/PF co-occurrence. The underlying mechanisms may be related to the regulation of critical targets (EGFR, SRC, MAPK3, MAPK1, MAPK8, AKT1, RELA, PIK3CA and so on) and EGFR, IL-17, TNF, HIF-1, PI3K/AKT and Toll-like receptor signaling pathways. This study contributes to guiding development of new drugs for COVID-19 and PF comorbidities.

5.
Diversity ; 14(5):343, 2022.
Article in English | ProQuest Central | ID: covidwho-1872007

ABSTRACT

Since the beginning of 2020, China has banned the consumption of wild animals to combat the spread of zoonoses. Most existing studies focus on the intention and behavior of wildlife consumption and their causes;however, few have looked at public willingness to resist wildlife consumption, as well as the cause and effects of such actions. In this study, a framework for an extended theory of planned behavior was constructed. Based on a 7-point Likert scale, a sample of 1194 respondents from eight provinces across China was obtained through an online survey. Structural equation modeling was used to analyze netizen behavioral intention to resist consuming wild animals and their causes to provide a reference for the implementation and optimization of relevant policies. The study model passed the goodness-of-fit test, confirming the robustness of the results. The results showed that Chinese netizens’ intention to resist consuming wild animals was moderate, with 55.19% willing to participate in activities against it, i.e., it is important to resist eating wild animals as a standard. Attitude, subjective norm, perceived behavioral control, and past experience of the Chinese netizen had significant positive effects on resistance intention, i.e., (1) netizens’ current living area with severe outbreaks were more likely to resist wildlife consumption, (2) highly knowledge level netizens were more likely to resist wildlife consumption than less knowledgeable ones, and (3) lower income level had higher behavioral intentions of netizens. The findings suggest that the government must take a lead role in wildlife protection and strengthen its restrictions, laws, and regulations. The media should also be used to promote conservation and popularize a protective message in favor of wild animals. Public quality and assurance of wildlife protection should be culturally reinforced to effectively ban the illegal trade of wild animals and their products.

6.
Sustainability ; 14(9):5325, 2022.
Article in English | MDPI | ID: covidwho-1820367

ABSTRACT

This paper investigates how investors respond to the COVID-19 pandemic, particularly regarding their intention to invest in sustainability-related investment (SRI) funds. We conduct two experiments online with participants who have experience with stock and fund investments. The first one includes 292 participants, which aims to explore investors' attitudes and investment intention of different sustainability-related components, and the second one includes 432 participants, which aims to examine how the COVID-19 pandemic affects individuals' attitudes and investment intention. Our results show that investors tend to invest in SRI funds when the threat of the COVID-19 pandemic is salient. Specifically, we find that although investors perceive environmental issues to be more important than economic and social issues, their investment intention of economic-focused SRI funds significantly increases in response to the COVID-19 pandemic threat. These findings suggest that fund managers can focus on particular types of investors when designing SRI funds, such as active investors with a preference for technical analysis and young female investors with a high level of income and education.

7.
Chemical Engineering Journal ; : 136499, 2022.
Article in English | ScienceDirect | ID: covidwho-1800162

ABSTRACT

Sepsis is a life-threatening condition originated from the accumulation of endotoxin in blood in response to infection (e.g., bacterial infection, COVID-19), and then aggravating by the systemic inflammatory responses, microcirculation disorders and oxidative stress, ultimately resulting in the dysfunction of multiple organs. Herein, advanced multi-lamellar microspheres (CPG-Ln-MSs) with cascade endotoxin adsorption and oxidative stress relief functions are constructed as an alternative adsorbent for hemoperfusion therapy towards sepsis. The CPG-Ln-MSs achieve effective endotoxin absorption (nearly 455.3 EU/g) and show excellent broad-spectrum radical scavenging activity for treating oxidative stress triggered by endotoxin accumulation. Specifically, the structural integrity of the multi-layered structure plays a vital role in promoting the efficiency of endotoxin removal and the subsequently scavenging of reactive oxygen species. Hemoperfusion simulation experiments demonstrate that the CPG-Ln-MSs could effectively remove endotoxin with a ratio of 92%, and the following oxidative stress state could be well alleviated, as confirmed by the reduced H2O2 and MDA levels in septic blood. Furthermore, endogenous antioxidants could be restored (recover SOD and CAT activity to 96.9 and 10.1 U/mL, respectively) and the red blood cells could be protected from oxidative damage. This study provides a promising therapeutic strategy and guides the design of future for septic blood purification.

8.
Front Psychol ; 13: 784444, 2022.
Article in English | MEDLINE | ID: covidwho-1753406

ABSTRACT

The purpose of the present study was to explore the direct influence of self-concept and self-imagination on English language learning outcomes (ELLO). Furthermore, this study examined the mediating role of self-efficacy in the relationship between self-concept, self-imagination, and ELLO. A survey questionnaire of 21 items was used in this study. We distributed the questionnaire through QR code and collected the data from 2,517 participants who enrolled in blended learning courses at the undergraduate level in Chinese universities. The relationship among the variables was measured through SmartPLS-SEM 3.3.3 (partial least squares structural equation modeling). The outcomes of the present study indicated a direct, positive, and significant connection of self-concept, self-imagination, and self-efficacy with ELLO. Looking at indirect influences, self-concept and self-imagination, positive and significant, influence ELLO through self-efficacy. Thus, self-efficacy was indicated to play a mediating role between self-concept, self-imagination and ELLO. We can conclude that self-concept, self-imagination, and self-efficacy are the main predictors of ELLO in blended learning courses during the pandemic. Additionally, self-concept and self-imagination along with the intervening role of self-efficacy, play a more effective role in improving ELLO. Moreover, this study provided some useful, practical implications, and future research directions.

9.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-322759

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic is straining global health resources and the prevalence of severe disease appears to vary across countries. In accordance with PRISMA guidelines, we performed a systematic review and meta-analysis of clinical features and underlying medical conditions of COVID-19. Eighty-seven studies, involving 1,434,931 COVID-19 patients from the Americas, Asia, Europe, and Oceania, were included. Geographically, the rate of severity was highest in Asia (95% confidence interval [CI] 0.23‒0.30). The rates of comorbidities of COVID-19 patients in the Americas were significantly higher than those in Asia. Most Asian patients had fever (95%CI 0.70‒0.81), and most Oceanian patients had cough (95%CI 0.68‒0.70) as their prevalent symptom. Dyspnea was common in the Americas (95%CI 0.33‒0.64), Europe (95%CI 0.29‒0.64), and high latitude regions (95%CI 0.53‒0.82). European patients exhibited significantly high rates of loss of smell and taste (95%CI 0.60-0.97). In low-latitude regions, cancer (95%CI 14.50‒4.89) had the strongest correlation with illness severity. Comorbid diseases and clinical manifestations of severe COVID-19 patients vary substantially between latitudes and longitudes. Region-specific care should be considered to treat and improve the prognosis of COVID-19 patients.

10.
Front Immunol ; 12: 769011, 2021.
Article in English | MEDLINE | ID: covidwho-1650341

ABSTRACT

Asthma patients may increase their susceptibility to SARS-CoV-2 infection and the poor prognosis of coronavirus disease 2019 (COVID-19). However, anti-COVID-19/asthma comorbidity approaches are restricted on condition. Existing evidence indicates that luteolin has antiviral, anti-inflammatory, and immune regulation capabilities. We aimed to evaluate the possibility of luteolin evolving into an ideal drug and explore the underlying molecular mechanisms of luteolin against COVID-19/asthma comorbidity. We used system pharmacology and bioinformatics analysis to assess the physicochemical properties and biological activities of luteolin and further analyze the binding activities, targets, biological functions, and mechanisms of luteolin against COVID-19/asthma comorbidity. We found that luteolin may exert ideal physicochemical properties and bioactivity, and molecular docking analysis confirmed that luteolin performed effective binding activities in COVID-19/asthma comorbidity. Furthermore, a protein-protein interaction network of 538 common targets between drug and disease was constructed and 264 hub targets were obtained. Then, the top 6 hub targets of luteolin against COVID-19/asthma comorbidity were identified, namely, TP53, AKT1, ALB, IL-6, TNF, and VEGFA. Furthermore, the enrichment analysis suggested that luteolin may exert effects on virus defense, regulation of inflammation, cell growth and cell replication, and immune responses, reducing oxidative stress and regulating blood circulation through the Toll-like receptor; MAPK, TNF, AGE/RAGE, EGFR, ErbB, HIF-1, and PI3K-AKT signaling pathways; PD-L1 expression; and PD-1 checkpoint pathway in cancer. The possible "dangerous liaison" between COVID-19 and asthma is still a potential threat to world health. This research is the first to explore whether luteolin could evolve into a drug candidate for COVID-19/asthma comorbidity. This study indicated that luteolin with superior drug likeness and bioactivity has great potential to be used for treating COVID-19/asthma comorbidity, but the predicted results still need to be rigorously verified by experiments.


Subject(s)
Anti-Inflammatory Agents/metabolism , Antioxidants/metabolism , Antiviral Agents/metabolism , Asthma/epidemiology , Asthma/metabolism , COVID-19/epidemiology , COVID-19/metabolism , Immunologic Factors/metabolism , Luteolin/metabolism , SARS-CoV-2/metabolism , Anti-Inflammatory Agents/chemistry , Antioxidants/chemistry , Antiviral Agents/chemistry , Comorbidity , Computational Biology/methods , Drug Discovery/methods , Humans , Immunologic Factors/chemistry , Interleukin-6/metabolism , Luteolin/chemistry , Molecular Docking Simulation , Protein Interaction Maps/drug effects , Proto-Oncogene Proteins c-akt/metabolism , Serum Albumin, Human/metabolism , Signal Transduction/drug effects , Tumor Necrosis Factor-alpha/metabolism , Tumor Suppressor Protein p53/metabolism , Vascular Endothelial Growth Factor A/metabolism
11.
Int J Therm Sci ; 172: 107371, 2022 Feb.
Article in English | MEDLINE | ID: covidwho-1606213

ABSTRACT

A cooperative control strategy is proposed for the air conditioning (AC) system and ventilation system to reduce the risk of COVID-19 infection and save the energy of the AC system. This strategy integrates the dynamic model of the AC-cabin system, infection risk assessment, model predictive control (MPC) of the thermal environment inside the cabin, and ventilation control that considers passengers' sneezing. Unlike other existing AC system models, the thermal-health model established can describe not only the system performance but also the virus concentration and risk of COVID-19 infection using the Wells-Riley assessment model. Experiments are conducted to verify the prediction accuracy of the AC-cabin model. The results prove that the proposed model can accurately predict the evolution of cabin temperature under different cases. The cooperative control strategy of the AC system integrates the MPC-based refrigeration algorithm for the cabin temperature and intermittent ventilation strategy to reduce the risk of COVID-19 infection. This strategy well balances the control accuracy, energy consumption of the AC system, and the risk of COVID-19 infection, and greatly reduces the infection risk at the expense of a little rise in the energy consumption.

12.
World J Clin Cases ; 9(31): 9481-9490, 2021 Nov 06.
Article in English | MEDLINE | ID: covidwho-1538856

ABSTRACT

BACKGROUND: The novel coronavirus disease 2019 (COVID-19) has spread widely around the world with strong infectivity, rapid mutation and a high mortality rate. Mechanical ventilation has been included in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 8) as an important treatment for severe and critical COVID-19 patients, but its clinical efficacy in COVID-19 patients is various. Therefore, it is necessary to study the influencing factors on the efficacy of mechanical ventilation in severe and critical COVID-19 patients. AIM: The aim of this study was to determine the influencing factors on the efficacy of mechanical ventilation in severe and critical COVID-19 patients. METHODS: A total of 27 severe and critical COVID-19 patients were enrolled in this study and treated with mechanical ventilation at the Optical Valley Campus of Hubei Maternal and Child Health Care Hospital (Wuhan, Hubei Province) from February 20, 2020 to April 5, 2020. According to the final treatment outcomes, the patients were divided into the "effective group" and "death group." The clinical data of the two groups, such as the treatment process and final outcome, were retrospectively analyzed in order to determine the specific curative effects on the two groups and the reasons for the differences in such curative effects, as well as to explore the factors related to death. RESULTS: This study enrolled 27 severe and critical COVID-19 patients, including 17 males (63.0%) and 10 females (37.0%). Their ages were 74.41 ± 11.73-years-old, and 19 patients (70.4%) were over 70-years-old. Severe COVID-19 patients over 70-years-old who were treated with mechanical ventilation died in 14 cases (82.4%); thus, this was the peak age. A total of 17 patients died of basic disease, 16 of whom had more than two basic diseases. The basic diseases were hypertension, diabetes, and cardiovascular and cerebrovascular diseases. At the same time, 13 patients (76.5%) died from an abnormal increase in blood glucose. Among them, eight had diabetes before contracting COVID-19 and five had a stress-induced increase in blood glucose after contracting COVID-19. Diabetic ketoacidosis occurred in one case. The use of tocilizumab may be a double-edged sword that carries a certain risk in clinical usage. Among the patients who died, 16 (94.1%) went into septic shock at the end. There were significant differences in the degree of infection, cardiac and renal function, and blood glucose between the death group and effective group. CONCLUSION: Age, blood glucose, cardiac and renal function, and inflammatory reaction are important indicators of poor prognosis for mechanical ventilation in severe and critical COVID-19 patients.

13.
J Med Internet Res ; 23(10): e28613, 2021 10 28.
Article in English | MEDLINE | ID: covidwho-1417034

ABSTRACT

BACKGROUND: As a distributed technology, blockchain has attracted increasing attention from stakeholders in the medical industry. Although previous studies have analyzed blockchain applications from the perspectives of technology, business, or patient care, few studies have focused on actual use-case scenarios of blockchain in health care. In particular, the outbreak of COVID-19 has led to some new ideas for the application of blockchain in medical practice. OBJECTIVE: This paper aims to provide a systematic review of the current and projected uses of blockchain technology in health care, as well as directions for future research. In addition to the framework structure of blockchain and application scenarios, its integration with other emerging technologies in health care is discussed. METHODS: We searched databases such as PubMed, EMBASE, Scopus, IEEE, and Springer using a combination of terms related to blockchain and health care. Potentially relevant papers were then compared to determine their relevance and reviewed independently for inclusion. Through a literature review, we summarize the key medical scenarios using blockchain technology. RESULTS: We found a total of 1647 relevant studies, 60 of which were unique studies that were included in this review. These studies report a variety of uses for blockchain and their emphasis differs. According to the different technical characteristics and application scenarios of blockchain, we summarize some medical scenarios closely related to blockchain from the perspective of technical classification. Moreover, potential challenges are mentioned, including the confidentiality of privacy, the efficiency of the system, security issues, and regulatory policy. CONCLUSIONS: Blockchain technology can improve health care services in a decentralized, tamper-proof, transparent, and secure manner. With the development of this technology and its integration with other emerging technologies, blockchain has the potential to offer long-term benefits. Not only can it be a mechanism to secure electronic health records, but blockchain also provides a powerful tool that can empower users to control their own health data, enabling a foolproof health data history and establishing medical responsibility.


Subject(s)
Blockchain , COVID-19 , Confidentiality , Data Management , Electronic Health Records , Humans , SARS-CoV-2
14.
J Med Internet Res ; 23(9): e24081, 2021 09 10.
Article in English | MEDLINE | ID: covidwho-1403378

ABSTRACT

BACKGROUND: The COVID-19 outbreak has now become a pandemic and has had a serious adverse impact on global public health. The effect of COVID-19 on the lungs can be determined through 2D computed tomography (CT) imaging, which requires a high level of spatial imagination on the part of the medical provider. OBJECTIVE: The purpose of this study is to determine whether viewing a 3D hologram with mixed reality techniques can improve medical professionals' understanding of the pulmonary lesions caused by COVID-19. METHODS: The study involved 60 participants, including 20 radiologists, 20 surgeons, and 20 medical students. Each of the three groups was randomly divided into two groups, either the 2D CT group (n=30; mean age 29 years [range 19-38 years]; males=20) or the 3D holographic group (n=30; mean age 30 years [range 20=38 years]; males=20). The two groups completed the same task, which involved identifying lung lesions caused by COVID-19 for 6 cases using a 2D CT or 3D hologram. Finally, an independent radiology professor rated the participants' performance (out of 100). All participants in two groups completed a Likert scale questionnaire regarding the educational utility and efficiency of 3D holograms. The National Aeronautics and Space Administration Task Load Index (NASA-TLX) was completed by all participants. RESULTS: The mean task score of the 3D hologram group (mean 91.98, SD 2.45) was significantly higher than that of the 2D CT group (mean 74.09, SD 7.59; P<.001). With the help of 3D holograms, surgeons and medical students achieved the same score as radiologists and made obvious progress in identifying pulmonary lesions caused by COVID-19. The Likert scale questionnaire results showed that the 3D hologram group had superior results compared to the 2D CT group (teaching: 2D CT group median 2, IQR 1-2 versus 3D group median 5, IQR 5-5; P<.001; understanding and communicating: 2D CT group median 1, IQR 1-1 versus 3D group median 5, IQR 5-5; P<.001; increasing interest: 2D CT group median 2, IQR 2-2 versus 3D group median 5, IQR 5-5; P<.001; lowering the learning curve: 2D CT group median 2, IQR 1-2 versus 3D group median 4, IQR 4-5; P<.001; spatial awareness: 2D CT group median 2, IQR 1-2 versus 3D group median 5, IQR 5-5; P<.001; learning: 2D CT group median 3, IQR 2-3 versus 3D group median 5, IQR 5-5; P<.001). The 3D group scored significantly lower than the 2D CT group for the "mental," "temporal," "performance," and "frustration" subscales on the NASA-TLX. CONCLUSIONS: A 3D hologram with mixed reality techniques can be used to help medical professionals, especially medical students and newly hired doctors, better identify pulmonary lesions caused by COVID-19. It can be used in medical education to improve spatial awareness, increase interest, improve understandability, and lower the learning curve. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2100045845; http://www.chictr.org.cn/showprojen.aspx?proj=125761.


Subject(s)
Augmented Reality , COVID-19 , Students, Medical , Adult , Humans , Lung , Male , SARS-CoV-2 , United States , Young Adult
15.
Intell Med ; 1(1): 16-18, 2021 May.
Article in English | MEDLINE | ID: covidwho-1293861

ABSTRACT

Coronavirus disease 2019 (COVID-19) made a huge effect globally. With the assistance of mixed reality (MR) technology, complicated clinical works became easier to carry out and the condition had been greatly improved with high-tech advantages such as improved convenience, better understanding and communication, higher security, and medical resource saving. This study aimed to introduce one kind of MR application in the fight against COVID-19 and anticipate more feasible smart healthcare applications to enhance our strength for the final victory.

16.
Int J Infect Dis ; 107: 5-11, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1220862

ABSTRACT

OBJECTIVE: The aim of this study was to evaluate the respiratory and physical function of patients who retested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA during post-coronavirus disease 2019 (COVID-19) rehabilitation. METHODS: A total of 302 discharged COVID-19 patients were included. Discharged patients were followed up for 14 days to 6 months. The modified Medical Research Council (mMRC) dyspnea scale, Borg rating of perceived exertion, and manual muscle testing (MMT) scores on day 14 and at 6 months after discharge were compared between the redetectable positive (RP) and non-RP (NRP) groups. Prognoses of respiratory and physical function were compared between patients who recovered from moderate and severe COVID-19. RESULTS: Of the study patients, 7.6% were RP. The proportion of patients who used antiviral drugs was significantly lower in the RP group than in the NRP group. There were no differences in mMRC, Borg, or MMT scores within the RP and NRP groups. The mMRC, Borg, and MMT scores were worse for patients with severe disease when compared to those with moderate disease at both follow-up time points. CONCLUSIONS: COVID-19 patients who did not take antiviral drugs were more likely to be RP after discharge. The recovery of respiratory and physical function was not related to re-positivity during rehabilitation, but was related to disease severity during hospitalization.


Subject(s)
COVID-19 Nucleic Acid Testing , COVID-19/physiopathology , Muscle Strength/physiology , Respiration , SARS-CoV-2 , Adolescent , Adult , Aged , COVID-19/virology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Patient Discharge , Severity of Illness Index , Young Adult
17.
Can Respir J ; 2021: 6692409, 2021.
Article in English | MEDLINE | ID: covidwho-1093889

ABSTRACT

We aimed to investigate changes in pulmonary function and computed tomography (CT) findings in patients with coronavirus disease 2019 (COVID-19) during the recovery period. COVID-19 patients underwent symptom assessment, pulmonary function tests, and high-resolution chest CT 6 months after discharge from the hospital. Of the 54 patients enrolled, 31 and 23 were in the moderate and severe group, respectively. The main symptoms 6 months after discharge were fatigue and exertional dyspnea, experienced by 24.1% and 18.5% of patients, respectively, followed by smell and taste dysfunction (9.3%) and cough (5.6%). One patient dropped out of the pulmonary function tests. Of the remaining 54 patients, 41.5% had pulmonary dysfunction. Specifically, 7.5% presented with restrictive ventilatory dysfunction (forced vital capacity <80% of the predicted value), 18.9% presented with small airway dysfunction, and 32.1% presented with pulmonary diffusion impairment (diffusing capacity for carbon monoxide <80% of the predicted value). Of the 54 patients enrolled, six patients dropped out of the chest CT tests. Eleven of the remaining 48 patients presented with abnormal lung CT findings 6 months after discharge. Patients with residual lung lesions were more common in the severe group (52.6%) than in the moderate group (3.4%); a higher proportion of patients had involvement of both lungs (42.1% vs. 3.4%) in the severe group. The residual lung lesions were mainly ground-glass opacities (20.8%) and linear opacities (14.6%). Semiquantitative visual scoring of the CT findings revealed significantly higher scores in the left, right, and both lungs in the severe group than in the moderate group. COVID-19 patients 6 months after discharge mostly presented with fatigue and exertional dyspnea, and their pulmonary dysfunction was mostly characterized by pulmonary diffusion impairment. As revealed by chest CT, the severe group had a higher prevalence of residual lesions than the moderate group, and the residual lesions mostly manifested as ground-glass opacities and linear opacities.


Subject(s)
COVID-19/physiopathology , Dyspnea/physiopathology , Fatigue/physiopathology , Lung/physiopathology , Adult , Aged , COVID-19/diagnostic imaging , Cough/physiopathology , Female , Follow-Up Studies , Forced Expiratory Volume , Humans , Lung/diagnostic imaging , Male , Middle Aged , Olfaction Disorders/physiopathology , Peak Expiratory Flow Rate , Pulmonary Diffusing Capacity , Recovery of Function , Respiratory Function Tests , SARS-CoV-2 , Severity of Illness Index , Taste Disorders/physiopathology , Tomography, X-Ray Computed , Vital Capacity
18.
SciFinder; 2020.
Preprint | SciFinder | ID: ppcovidwho-5248

ABSTRACT

The study was designed to explore the mol. mechanism of Huopuxialing Decoction for the treatment of corona virus disease (COVID-19) based on network pharmacol., and provide new ideas for its clin. treatment and laboratory research. The results show Huopuxialing Decoction may treat COVID-19 by intervening inflammatory response, immune regulation and apoptosis through multiple targets and multiple pathways.

19.
Tianjin Medical Journal ; 48(10):916-919, 2020.
Article in Chinese | GIM | ID: covidwho-976574

ABSTRACT

Objective: To explore the risk factors of subsequent bacterial infection in patients with novel coronavirus disease 2019 (COVID-19).

20.
Chinese J. Lab. Med. ; 5(43): 511-514, 20200511.
Article in Chinese | WHO COVID, ELSEVIER | ID: covidwho-769444

ABSTRACT

During the outbreak of COVID-19, the clinical laboratories of hospitals designated for the disease treatment are undertaking a lot of clinical testing work of infectious specimens. How to manage the biosafety risk is a major problem that the clinical laboratories and the departments of nosocomial infection control are facing. This article introduces the hierarchical prevention and control of biosafety risk from the perspective of the laboratory, with a view to provide reasonable and feasible methods for the clinical laboratories of hospitals at various levels during the outbreak.

SELECTION OF CITATIONS
SEARCH DETAIL